Skip to main content
Clinical Trials/NCT04792814
NCT04792814
Completed
Not Applicable

Intraoperative Cell Salvage and Retrograde Autologous Priming in Patients Undergoing Isolated Coronary Bypass Grafting and Conventional Aortic Valve Replacement.

University Hospital Schleswig-Holstein2 sites in 1 country200 target enrollmentJune 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Surgery
Sponsor
University Hospital Schleswig-Holstein
Enrollment
200
Locations
2
Primary Endpoint
number of red blood cell concentrates
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

In recent years Patient Blood Management (PBM) has developed into a multifactorial and interdisciplinary concept that focuses on individualized and optimized hemotherapy. Of course, this also applies to the cardiac surgery area (1). In this context, the quality of the intraoperative PBM can be represented by patients scheduled for isolated coronary artery bypass grafting (CABG) and isolated aortic valve replacement (AVR). In a prospective, observational "before-and-after" protocol, the investigators analysed the impact of the combined use of retrograde autologous priming (RAP) and cell salvage on intraoperative usage of red blood cell concentrates (RBC) (2).

Detailed Description

200 patients (CABG or AVR) will be monitored using local standard of care in these patients without cell salvage and RAP (control group, CG), followed by 200 patients with cell salvage and RAP (study group, SG). Both groups are defined by elective surgery and hemodynamically stable patients prior to the onset of the cardiopulmonary bypass (CPB). Based on our own data and current data from the literature, the investigators assume that the use of MAT in combination with RAP leads to at least an intraoperative reduction of the erythrocyte consumption of 15%. Consequently, the investigators calculated a case number of approximately 200 patients per group. The study is set up with a control group under previous standard therapy. The data is recorded and analyzed descriptively. Qualitative comparisons will be made in the discussion of previously published data.

Registry
clinicaltrials.gov
Start Date
June 1, 2018
End Date
October 31, 2019
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital Schleswig-Holstein
Responsible Party
Principal Investigator
Principal Investigator

Dr. Jochen Renner

Prof. Dr. med. Jochen Renner

University Hospital Schleswig-Holstein

Eligibility Criteria

Inclusion Criteria

  • scheduled for cardiac surgery
  • informed written consent

Exclusion Criteria

  • rejection by the patient
  • switching to another procedure

Outcomes

Primary Outcomes

number of red blood cell concentrates

Time Frame: through study completion, an average of 1 year

use of RBC

Secondary Outcomes

  • postoperative complications(through study completion, an average of 1 year)
  • length of stay in hospital(through study completion, an average of 1 year)
  • hospital mortality(through study completion, an average of 1 year)

Study Sites (2)

Loading locations...

Similar Trials